A Single-Arm, Open-label, Phase II Study Evaluating Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors - (POSTPONE)
Latest Information Update: 13 Nov 2025
At a glance
- Drugs Pacritinib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms POSTPONE
Most Recent Events
- 13 Nov 2025 New trial record